These findings, together with those previously reported for other tumor types, support the concept that during the course of treatment with chemotherapy, cisplatin selects for a subset of drug-resistant ALDH1+ve stem cells, which may explain, at least in part, relapse of NSCLC patients following prolonged treatment with cisplatin. The gene discussed is ALDH1A1; the disease is non-small cell lung carcinoma.